Across TCGA pan-cancer cohorts, IGHV1-3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of IGHV1-3’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where IGHV1-3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGHV1-3 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.
LUAD, HNSC, and PDAC are the cancer types where IGHV1-3 tumor–normal differential expression is most reproducible.